US COVID-19 study completes recruitment

Brisbane, Australia, 10 January 2022 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce that it has completed recruitment in its US-based SARS-CoV2 ("COVID-19") clinical study, COVID-Cough. The study has now collected audio cough recordings and self-reported symptoms for 122 polymerase chain reaction (PCR) confirmed COVID-19 positive cases and 139 PCR confirmed COVID-19 negative cases.

The US-based COVID-Cough pilot clinical study (clinicaltrials.gov: NCT04864535) aims to collect data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone, using a gold standard PCR pathology test as a reference standard (ref ASX announcements 11 March 2021 and 15 November 2021).

CEO and Managing Director, Dr Tony Keating said: *"We greatly appreciate the support of all participants who enrolled in the study and the work of our partners, Phosphorus and Covid Clinic in helping us complete recruitment. This US data, as well as data from our recently completed Indian clinical study and our datasets collected pre-COVID-19, provides us with a high-quality clinical dataset to build, train and validate algorithms for detection and monitoring of COVID-19.*

"As the fourth wave of COVID-19 spreads worldwide, our team is working hard to deliver algorithms for a much-needed, instant smartphone-based screening test and patient monitoring tools that could change the way the world lives with this virus."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.